Details for Patent: 8,779,131
✉ Email this page to a colleague
Title: | 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
Abstract: | Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below. ##STR00001## |
Inventor(s): | Kesicki; Edward A. (Seattle, WA), Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Puri; Kamal Deep (Lynnwood, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA) |
Assignee: | Icos Corporation (Indianapolis, IN) |
Filing Date: | Feb 12, 2013 |
Application Number: | 13/765,610 |
Claims: | 1. A method comprising inhibiting phosphatidylinositol 3-kinase activity in a cell with a compound ##STR00186## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the compound is ##STR00187## 4. The method of claim 1, further comprising administering the compound or a pharmaceutically acceptable salt thereof to an individual in need thereof. 5. The method of claim 4, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 6. The method of claim 4, wherein the compound is the S-enantiomer. 7. A method of inhibiting phosphatidylinositol 3-kinase delta activity in a cell, comprising administering to an individual in need thereof the compound ##STR00188## or a pharmaceutically acceptable salt thereof. 8. The method of claim 7, wherein the compound is ##STR00189## 9. The method of claim 7, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 10. The method of claim 7, wherein the compound is the S-enantiomer. |